(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
The Most recent Microsoft Surface Genius PC: Ideal for Very good quality Planning and Gaming Needs- A Pompeii site reveals the recipe for Roman concrete. It contradicts a famous architect’s writings
- Liste des pr\u00eats qui ne n\u00e9cessitent pas de remboursement
- Most loved Road Food: Which One Prevails upon You?
- Decrease in Home Buy Credits and Home loan Renegotiating Rates: An Outline of Latest things
- Nodding off is dangerous. Some animals have evolved extreme ways to sleep in precarious environments
- Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
- Cuba says 33 have died of mosquito-borne illnesses as epidemic rages
